on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Partners with Chinese Joint Venture for Actinium-225 Production
Eckert & Ziegler SE announced a strategic licence agreement with Qi Kang Medical, Ltd, a joint venture with DC Pharma, to utilize cyclotron technology for producing Actinium-225 (Ac-225). This agreement entails a one-time payment of EUR 10 million to Eckert & Ziegler, along with royalties from Ac-225 sales.
This collaboration marks a significant development for Eckert & Ziegler, positioning it as a leading supplier of Ac-225 in the radiopharmaceutical industry. The company plans to significantly increase Ac-225 production by 2025, ensuring GMP quality standards.
Ac-225 is currently being tested in clinical trials for treating cancers such as prostate tumors, colorectal cancer, and leukemia. The demand for Ac-225 is expected to rise substantially over the next decade due to its promising clinical results. Despite its potential, Ac-225 remains a scarce resource.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news